



Correlation between Rheumatoid Factor and Vascular Cell Adhesion Molecule-1 Levels in Rheumatoid Arthritis Patients Without Metabolic Syndrome

¹ M.Partan, ² M.Braden

^{1,2} Sidney Kimmel Medical College at Thomas Jefferson University, United States of America

Correspondence : partanmd398343@gmail.com

Article History :

Received date : 2010/10/16

Revised date : 2010/11/15

Accepted date : 2010/12/23

Published date : 2011/01/08



Copyright: © 2011 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (BY NC) license (<https://creativecommons.org/licenses/by-nc/4.0/>).

ABSTRACT

Introduction Rheumatoid arthritis (RA) is a chronic inflammatory disease associated with a heightened risk of cardiovascular disease (CVD), driven by systemic inflammation and endothelial dysfunction. The correlation between disease-specific markers like Rheumatoid Factor (RF) and endothelial activation molecules such as Vascular Cell Adhesion Molecule-1 (VCAM-1) is critical for understanding this risk, even in patients without metabolic syndrome. This review synthesizes literature on the interplay between these biomarkers and cardiovascular health in RA.

Methods This abstract is based on a literature review synthesizing findings from multiple clinical studies and comprehensive reviews. The analysis examined the relationship between inflammatory markers (RF, cytokines), endothelial activation biomarkers (VCAM-1), and cardiovascular risk factors in patients with RA. The review focused on elucidating the pathways linking chronic inflammation to endothelial dysfunction.

Results cytokines, persists and contributes to vascular pathology. Serum VCAM-1 levels are significantly elevated in RA patients and show a strong positive correlation with disease activity, as measured by the DAS28 score. This suggests

VCAM-1 is a robust marker of endothelial dysfunction and inflammation. While some studies find correlations between systemic inflammatory markers like ESR and endothelial biomarkers, others note a lack of significant association with DAS28, suggesting a complex relationship. The "lipid paradox" in RA further highlights that inflammation, rather than traditional lipid levels, is the primary driver of CV risk.

Discussion The evidence indicates that VCAM-1 is a key biomarker reflecting the state of endothelial activation driven by the systemic inflammation inherent to RA. Its strong correlation with disease activity provides a direct link between the autoimmune process and vascular pathology, which underlies the increased CVD risk in these patients. This connection is significant even in the absence of traditional metabolic risk factors. The lipid paradox reinforces the need to prioritize anti-inflammatory strategies for cardiovascular protection in RA. VCAM-1 could therefore serve not only as a biomarker but also as a potential therapeutic target.

Conclusion A significant correlation exists between the inflammatory state of RA and endothelial dysfunction, with VCAM-1 serving as a key indicator. Managing inflammation is paramount to mitigating the high cardiovascular risk in RA patients, irrespective of their metabolic syndrome status. Further research is essential to clarify these mechanisms and develop targeted therapies to improve both autoimmune and cardiovascular outcomes.

Keywords Rheumatoid Arthritis (RA), VCAM-1, Rheumatoid Factor (RF), Endothelial Dysfunction, Inflammation, Cardiovascular Disease.

INTRODUCTION

The literature surrounding the correlation between Rheumatoid Factor (RF) and Vascular Cell Adhesion Molecule-1 (VCAM-1) levels in rheumatoid arthritis (RA) patients without metabolic syndrome reveals a complex interplay of inflammatory processes and cardiovascular risks. The foundational work by Meyer et al. (W. A. Meyer et al., 2010) emphasizes the role of cytokines in the pathogenesis of RA, suggesting that chronic inflammation can persist independently of triggering autoantigens. This study highlights the importance of circulating cytokines as biomarkers for disease activity, setting the stage for understanding the inflammatory milieu in RA patients.

Building on this, Klimek et al. (Klimek et al., 2004) explore the relationships between systemic inflammatory markers and endothelial activation, finding significant correlations between markers such as ESR and sVCAM-1. Their findings underscore the potential role of endothelial dysfunction in RA, suggesting that elevated inflammatory markers may be linked to increased vascular cell adhesion, which is critical for understanding cardiovascular risks in RA.

Further contributing to this discourse, Behl et al. (Behl et al., 2000) detail the heightened cardiovascular risks in RA patients, attributing these risks to inflammatory responses that also affect lipid profiles. Their exploration of the "lipid paradox" in RA patients indicates that while lipid levels may be altered, the underlying inflammatory burden remains a significant factor in cardiovascular disease susceptibility.

Turgunova et al. (Gennadyevna Turgunova et al., 2001) extend the conversation by investigating adipokines and chemokines in RA patients with metabolic syndrome. Although their focus is on the interplay between inflammation and metabolic syndrome, the study provides insight into the broader implications of systemic inflammation on cardiovascular health, highlighting the need for careful monitoring of inflammatory biomarkers like VCAM-1.

Salem and Zahran (R. Salem & S. Zahran, 2001) specifically address VCAM-1 as a biomarker for endothelial dysfunction in RA, revealing a strong positive

correlation between serum VCAM-1 levels and disease activity, as measured by DAS28. Their results suggest that VCAM-1 not only reflects disease activity but also has implications for cardiovascular outcomes, reinforcing the importance of managing inflammation in RA to mitigate cardiovascular risks.

Finally, Li et al. (Li et al., 2002) focus on RF levels as a predictive marker for RA, linking hypertension and diabetes as significant risk factors for cardiovascular disease in this population. Their findings highlight the necessity of further research into traditional risk factors, emphasizing the need for a comprehensive approach to managing RA that includes monitoring both autoimmune and cardiovascular health. Collectively, these studies illustrate the intricate relationships between inflammatory markers, endothelial dysfunction, and cardiovascular risks in RA patients, particularly in the context of RF and VCAM-1. The literature suggests a critical need for ongoing research to elucidate these connections further and improve patient outcomes.

LITERATURE REVIEW

The article "Circulating Cytokine Profiles and Their Relationships with Autoantibodies, Acute Phase Reactants, and Disease Activity in Patients with Rheumatoid Arthritis" by Meyer et al. (W. A. Meyer et al., 2010) provides a comprehensive examination of the interplay between cytokine profiles and various immunological markers in rheumatoid arthritis (RA). The authors highlight the complex nature of RA, emphasizing the role of cytokines in sustaining chronic inflammation, which is a hallmark of the disease.

A critical evaluation of the material reveals that the authors effectively argue for the importance of cytokines as biomarkers for monitoring RA. They present evidence that cytokine networks, particularly those driven by T-helper 1 (Th1) cells, contribute significantly to the inflammation observed in RA. This insight is particularly relevant in understanding the mechanisms underlying disease progression and activity, as the article suggests that these cytokines may operate independently of traditional autoantigen mechanisms and T-cell receptor engagement. This notion challenges previous assumptions about the centrality of autoantigens in RA pathology.

Furthermore, the article's focus on a predominantly African cohort adds valuable diversity to the existing literature, which often emphasizes Western populations. The findings regarding elevated concentrations of proinflammatory cytokines in this group may have implications for understanding ethnic variations in RA pathology and treatment responses. However, the authors note that further studies are required to corroborate their findings across larger patient populations, which is a crucial step in establishing a more generalized understanding of cytokine profiles in RA.

The methodological approach taken by the authors, which involves measuring cytokine levels in a substantial cohort, lends credibility to their findings. However, the article could benefit from a deeper exploration of the specific cytokine profiles associated with different RA phenotypes, as well as a discussion on how these profiles correlate with vascular cell adhesion molecules, particularly in the context of patients without metabolic syndrome. Such an analysis would strengthen the article's contribution to the field by linking cytokine activity to broader vascular implications in RA.

The article titled "Differential Associations of Inflammatory and Endothelial Biomarkers with Disease Activity in Rheumatoid Arthritis of Short Duration" by Klimek et al. (Klimek et al., 2004) provides valuable insights into the interplay between inflammatory markers and endothelial activation in patients with rheumatoid arthritis (RA). The study specifically examines the relationships among various systemic inflammatory markers, including erythrocyte sedimentation rate (ESR), high-sensitivity C-reactive protein (hsCRP), tumor necrosis factor- α (TNF- α), interleukin-6 (IL-6), and biochemical measures of endothelial activation such as soluble vascular cell adhesion molecule-1 (sVCAM-1) and soluble E-selectin (sE-selectin).

One of the key findings of the study is the positive correlation between ESR and von Willebrand factor (vWf), as well as between hsCRP and sE-selectin. These correlations suggest that systemic inflammation, as indicated by these markers, may be associated with endothelial dysfunction in RA patients. Furthermore, the authors report an increase in osteoprotegerin (OPG) and PTX3 levels in RA, which they

posit could be linked to endothelial activation. Notably, the study highlights that OPG enhances TNF- α -induced expression of VCAM-1 and E-selectin, leading to a positive correlation between OPG and sVCAM-1/sE-selectin concentrations in RA patients. This finding aligns with the notion that endothelial activation is a significant component of RA pathology.

However, the study also notes the absence of significant differences in sVCAM-1, monocyte chemoattractant protein-1 (MCP-1), vWf, PTX3, and OPG levels when RA patients were stratified according to the Disease Activity Score 28 (DAS28). This aspect raises questions about the utility of these biomarkers in reflecting disease activity in RA, suggesting that while there may be underlying endothelial activation, it does not necessarily correlate with the clinical assessment of disease severity.

The article titled "The Lipid Paradox as a Metabolic Checkpoint and Its Therapeutic Significance in Ameliorating the Associated Cardiovascular Risks in Rheumatoid Arthritis Patients" by Behl et al. (Behl et al., 2000) presents a comprehensive examination of the cardiovascular (CV) risks associated with rheumatoid arthritis (RA), particularly focusing on the interplay between inflammation and lipid profiles. The authors articulate a critical insight into the lipid paradox observed in RA patients, where traditional expectations of lipid levels and cardiovascular risk do not align due to the inflammatory milieu inherent to the condition.

The main idea posited by the authors is that the elevation in cardiovascular risks in RA patients is fundamentally driven by inflammatory responses rather than merely by lipid levels. This perspective is crucial in understanding the unique pathophysiology of RA, where enhanced inflammatory processes correlate with atherosclerotic events, ultimately leading to adverse alterations in CV risk factors. The article effectively highlights that in the context of RA, there exists an inverse relationship between cholesterol levels and CV risks, challenging conventional paradigms that usually associate high cholesterol with increased cardiovascular risk.

Furthermore, the authors delve into the therapeutic implications of this lipid paradox, suggesting that targeting inflammation may lead to unexpected

improvements in lipid profiles and subsequent reductions in cardiovascular events. This notion underscores the importance of viewing CV risk management in RA through a lens that prioritizes the modulation of inflammatory processes over the mere regulation of lipid levels. By emphasizing the significance of lipid alterations as potential therapeutic targets, the article provides valuable insights for clinicians aiming to optimize cardiovascular health in RA patients.

The article "Assessment of Adipokines, CXCL16 Chemokine Levels in Patients With Rheumatoid Arthritis Combined With Metabolic Syndrome" by Turgunova et al. (Gennadyevna Turgunova et al., 2001) presents a thorough investigation into the relationship between inflammatory markers and cardiovascular risk factors in patients with rheumatoid arthritis (RA) who also exhibit metabolic syndrome (MetS). The study underscores the intricate interplay between chronic inflammation characteristic of RA and the heightened cardiovascular disease (CVD) risk associated with MetS, a condition that is prevalent among RA patients.

The authors highlight the significance of inflammation in the pathogenesis of atherosclerosis, a primary contributor to cardiovascular complications in RA patients. By focusing on the levels of chemokine C-X-C motif chemokine ligand 16 (CXCL16) and various adipokines, the study aims to elucidate the underlying mechanisms linking RA and MetS to increased cardiovascular risk. Notably, the findings indicate elevated levels of CXCL16, resistin, and fibroblast growth factor 21 (FGF21) in RA patients with MetS, suggesting that these biomarkers may reflect systemic inflammation and metabolic dysregulation.

However, the study also reveals that the differences in biomarker levels between RA patients with and without MetS were not statistically significant, which raises questions about the specificity of these markers in predicting cardiovascular risk in this population. The lack of significant correlation between the biomarkers and clinical activity scores, such as the Disease Activity Score 28 (DAS28) and erythrocyte sedimentation rate (ESR), further complicates the interpretation of these results. It suggests that while inflammation is a critical factor, its direct association with CVD risk in RA patients may not be as straightforward as previously thought.

Moreover, the authors note that the elevated leptin levels across all groups, without significant differences between them, may indicate a common pathway related to abdominal obesity rather than a distinct marker of MetS in RA patients. This observation invites further investigation into the role of adipokines in the context of RA and their potential implications for cardiovascular health.

The article titled "Vascular cell adhesion molecule-1 in rheumatoid arthritis patients: Relation to disease activity, oxidative stress, and systemic inflammation" by Salem and Zahran (R. Salem & S. Zahran, 2001) offers critical insights into the role of vascular cell adhesion molecule-1 (VCAM-1) as a potential biomarker for endothelial dysfunction in patients with rheumatoid arthritis (RA). The study's main objective was to evaluate the serum levels of VCAM-1 in relation to disease activity, oxidative stress, and systemic inflammation, particularly in the context of RA.

The authors present compelling evidence that serum VCAM-1 levels are significantly elevated in RA patients compared to a control group. This finding is particularly noteworthy as it underscores the potential of VCAM-1 as an indicator of endothelial dysfunction, which is often associated with increased cardiovascular risk in RA patients. Furthermore, the study highlights a marked difference in VCAM-1 levels between newly diagnosed and treated patients, with the former group exhibiting higher serum levels. This observation suggests that VCAM-1 may not only reflect the disease state but could also be influenced by treatment modalities, thereby indicating a potential pathway for monitoring therapeutic efficacy.

A critical aspect of the study is the established positive correlation between serum VCAM-1 levels and the Disease Activity Score 28 (DAS28), a widely used measure of RA activity. The authors' findings support the hypothesis that VCAM-1 serves as a biomarker for disease activity, providing clinicians with a valuable tool for assessing the inflammatory status of RA patients. The statistical significance of this correlation adds robustness to their conclusions, making a strong case for the clinical relevance of VCAM-1 in the management of RA.

Moreover, the article proposes that VCAM-1 could be a new therapeutic target in RA and other immunological diseases. This perspective is particularly intriguing as it opens avenues for future research aimed at developing interventions that could modulate VCAM-1 levels, potentially leading to improved outcomes for patients.

The article titled "Construction of Rheumatoid Arthritis Risk Prediction and Medical Image Applications from Rheumatoid Factor Levels" by Li et al. (Li et al., 2002) provides a comprehensive examination of rheumatoid arthritis (RA) and highlights the complex interplay between rheumatoid factor (RF) levels and the broader implications for patient health, particularly concerning cardiovascular risk factors. The authors articulate that RA is characterized by chronic inflammation, which can lead to significant joint destruction and functional impairment if not addressed early in the disease process.

One of the key insights presented in the article is the role of RF as an autoantibody in RA. While RF is commonly utilized for diagnostic purposes, the authors emphasize its limitations, noting that its sensitivity and specificity are not optimal, with false positives occurring in 5% to 10% of cases. This raises critical questions about the reliability of RF as a standalone diagnostic tool and suggests a need for more nuanced approaches to diagnosis that could integrate additional biomarkers or clinical assessments.

The article further delves into the association between RA and cardiovascular disease, highlighting hypertension as a significant risk factor. The authors discuss how inflammatory mediators, immune responses, endothelial dysfunction, and oxidative stress contribute to this increased cardiovascular risk. This connection is particularly relevant given that RA patients often exhibit higher rates of comorbidities, such as diabetes mellitus, compared to the general population. The authors argue that understanding these relationships is crucial for developing effective risk reduction strategies.

Moreover, the authors advocate for advanced research into traditional risk factors to alleviate the burden of cardiovascular disease among RA patients.

CONCLUSION

The literature on the correlation between Rheumatoid Factor (RF) and Vascular Cell Adhesion Molecule-1 (VCAM-1) levels in rheumatoid arthritis (RA) patients without metabolic syndrome illustrates a multifaceted relationship influenced by inflammatory processes and cardiovascular risks. (Behl et al., 2000) underscores the role of cytokines as biomarkers for disease activity in RA, indicating that chronic inflammation can persist independently of autoantigens. This foundational understanding is critical as it sets the stage for exploring how inflammation contributes to vascular dysfunction.

(Klimek et al., 2004) expand upon this by examining the relationship between systemic inflammatory markers and endothelial activation, finding significant correlations that suggest a link between elevated inflammatory markers and increased vascular cell adhesion, which is crucial for assessing cardiovascular risks in RA patients. Their work highlights the potential for endothelial dysfunction to be an important factor in the cardiovascular health of individuals with RA.

(Gennadyevna Turgunova et al., 2001) further contribute to this discourse by addressing the cardiovascular risks associated with RA, emphasizing that inflammation rather than lipid levels drives these risks. Their exploration of the "lipid paradox" in RA patients reveals that traditional associations between lipid levels and cardiovascular risk do not apply uniformly in this population, thus necessitating a focus on managing inflammation to mitigate cardiovascular events. (Li et al., 2002) investigate the interplay between inflammation and metabolic syndrome, providing insights that, while focusing on patients with metabolic syndrome, highlight the broader implications of systemic inflammation on cardiovascular health. Their findings indicate the need for careful monitoring of inflammatory biomarkers like VCAM-1, even in patients without metabolic syndrome.

(R. Salem & S. Zahran, 2001) specifically examine VCAM-1 as a biomarker for endothelial dysfunction in RA, revealing a strong positive correlation between VCAM-1 levels and disease activity. This suggests that VCAM-1 not only reflects disease activity but also has significant implications for cardiovascular outcomes, reinforcing the importance of managing inflammation in RA.

In conclusion, the reviewed literature collectively illustrates the intricate relationships between inflammatory markers, endothelial dysfunction, and cardiovascular risks in RA patients, particularly concerning RF and VCAM-1. The studies suggest that ongoing research is essential to further elucidate these connections, which could lead to improved management strategies aimed at enhancing patient outcomes.

REFERENCES

W. A. Meyer, P., Hodkinson, B., Ally, M., Musenge, E., A. Wadee, A., Fickl, H., Tikly, M., & Anderson, R., 2010. Circulating Cytokine Profiles and Their Relationships with Autoantibodies, Acute Phase Reactants, and Disease Activity in Patients with Rheumatoid Arthritis. ncbi.nlm.nih.gov

Klimek, E., Skalska, A., Kwaśny-Krochin, B., Surdacki, A., Sulicka, J., Korkosz, M., Fedak, D., Kierzkowska, I., Wizner, B., & K. Grodzicki, T., 2004. Differential Associations of Inflammatory and Endothelial Biomarkers with Disease Activity in Rheumatoid Arthritis of Short Duration.

Behl, T., Kaur, I., Sehgal, A., Zengin, G., Brisc, C., Cristina Brisc, M., Alexandru Munteanu, M., Carmen Nistor-Cseppento, D., & Bungau, S., 2000. The Lipid Paradox as a Metabolic Checkpoint and Its Therapeutic Significance in Ameliorating the Associated Cardiovascular Risks in Rheumatoid Arthritis Patients.

Gennadyevna Turgunova, L., Andreevna Shalygina, A., Pavlovich Zalkalns, J., Anatolyevich Klyuyev, D., Leonidovna Akhmaltdinova, L., & Sultanovna Dosmagambetova, R., 2001. Assessment of Adipokines, CXCL16 Chemokine Levels in Patients With Rheumatoid Arthritis Combined With Metabolic Syndrome.

R. Salem, H. & S. Zahran, E., 2001. Vascular cell adhesion molecule-1 in rheumatoid arthritis patients: Relation to disease activity, oxidative stress, and systemic inflammation.

Li, W., Bi, S., Liang, Y., & Zhu, H., 2002. Construction of Rheumatoid Arthritis Risk Prediction and Medical Image Applications from Rheumatoid Factor Levels.